Drug intelligence / Profile preview

YL-23174

Development stage: Unknown
Lead developer: Rila Therapeutics
Modality: Small Molecules

Overview

YL-23174 is a small molecule inhibitor of Homeodomain-interacting protein kinase 2 (HIPK2) being developed by Yingli Pharmaceutical for the treatment of fibrosis. HIPK2 is a serine/threonine kinase that acts as a central hub in the regulation of fibrotic processes by integrating signals from various pro-fibrotic pathways, including TGF-β, Notch, and Wnt/β-catenin. Overexpression or overactivation of HIPK2 has been linked to the progression of fibrosis in organs such as the kidney and liver. By inhibiting HIPK2, YL-23174 aims to suppress the activation of myofibroblasts and reduce the accumulation of extracellular matrix. The drug is currently in Phase 1 clinical trials in both China and the United States.

Targets

HIPK2 (Homeodomain-interacting protein kinase 2)

Beyond the preview

Go deeper on YL-23174.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YL-23174.

Explore the full profile